The Salk approach, tested in a mouse model, points to cheaper and more effective treatments for humans
For most people with hemophilia B, whose bodies can’t properly form blood clots, constant injections to replenish their clotting factors are a way of life. But now, Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. The finding, published in the journal Cell Reports on May 1, 2018, could drastically change what it means to be diagnosed with hemophilia B, and could pave the way toward similar treatments for other, related genetic disorders.
Hemophilia B is caused by defects in the gene for a protein called clotting factor IX (FIX). Hemophiliacs may make reduced amounts of the protein, or lack a functional version altogether, leading to life-threatening delays in blood clotting. Currently, patients are treated with injections—as often as a few times a week—containing FIX made in animal cells and then purified. But the approach is expensive, time-consuming and can become less effective over time.
Recently, Salk scientists developed a new approach, treating mice genetically engineered to have hemophilia B with strands of messenger RNA encoding the FIX gene. Like the standard treatment, however, this required repeat injections each time levels of the messenger RNA ran low. So the scientists wanted to try a more permanent approach: transplanting healthy liver cells, capable of producing FIX, into patients.
“The appeal of a cell-based approach is that you minimize the number of treatments that a patient needs,” says Suvasini Ramaswamy, a former Salk research associate in the Verma lab and first author of the new paper. “Rather than constant injections, you can do this in one shot.”
Since donor livers are often in short-supply, the researchers instead turned to stem-cell strategies to produce the healthy liver cells. They collected blood samples from two human patients with severe hemophilia B, who are unable to produce FIX. Then, in the lab, they reprogrammed the cells into induced pluripotent stem cells (iPSCs), which have the capability to turn into many other cell types, including liver. Using CRISPR/Cas9, a tool that can alter genes, they then repaired the mutations in each patient’s FIX gene. Finally, they coaxed those repaired cells to develop into liver precursor cells called hepatocyte-like cells (HLCs) and transplanted them into mice with hemophilia B.
Rather than perform surgery on hemophilic mice—a risky undertaking when their blood can’t always clot—the team transplanted the HLCs through the spleen to distribute the cells uniformly in the liver.
Not only did the new HLCs produce FIX, but they produced enough of the protein to allow the mice to form normal blood clots, and the cells continued to survive—and produce FIX—for at least a year after the transplantation.
In people with hemophilia, using their own cells to generate healthy HLCs, then transplanting them back into their bodies, could help avoid the immune complications that often accompany cell therapies. But more work is needed to translate the findings to the clinic.
“A lot of things have to happen before this can go into humans,” says Ramaswamy.
Already, she adds, the work demonstrates the value in combining stem-cell reprogramming and new gene-modifying approaches to treat genetic diseases.
The Latest on: Hemophilia B
via Google News
The Latest on: Hemophilia B
- uniQure Stocks Up With First Phase III Results of Hemophilia B Gene Therapyon November 27, 2020 at 5:52 am
Gene therapies for the rare blood clotting disorder hemophilia B have taken a step closer to the market as Dutch developer uniQure became the first to release interim phase III results last week.
- Latest spinoff from UNC’s Gene Therapy Center wants to find a cure for hemophilia | Raleigh News & Observeron November 27, 2020 at 5:08 am
UNC’s Gene Therapy Center has been prolific in generating startups in recent years. Its latest focuses on the rare blood disorder hemophilia.
- Hemophilia A Treatment Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2022on November 26, 2020 at 2:51 pm
The Hemophilia A Treatment Market report upholds the future market predictions related to Hemophilia A Treatment market size, revenue, production, Consumption, gross margin and other substantial ...
- Pfizer (PFE) Begins Phase III Study on Hemophilia Candidateon November 24, 2020 at 8:39 am
Pfizer Inc. PFE announced that it has dosed the first participant in a phase III study, which is evaluating its anti-tissue factor pathway inhibitor (anti-TFPI) marstacimab for the treatment of ...
- uniQure rises on hemophilia B gene therapy dataon November 19, 2020 at 1:00 pm
Qure (QURE +7.3%) has announced positive data from a closely watched pivotal (Phase 3) study of its hemophilia B gene therapy.
- UniQure's hemophilia drug shows benefit over Pfizer'son November 19, 2020 at 11:45 am
UniQure N.V., which has US headquarters in Lexington, is heading to the FDA after its lead drug for the blood disorder hemophilia B succeeded in a late-stage trial. The company said the results were ...
- UniQure Rallies On Positive Late-Stage Data For Hemophilia B Gene Therapyon November 19, 2020 at 11:08 am
UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, ...
- uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia Bon November 19, 2020 at 8:06 am
Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~ ~ Patients achieved significant increases in Factor IX activity irrespective of ...
- Gene therapy hemophilia B 'cure' approach heats up as uniQure/CSL, rivaling Pfizer, shows promiseon November 19, 2020 at 6:36 am
CSL Behring and uniQure’s hemophilia B gene therapy etranacogene dezaparvovec hit its primary endpoint in an ASH late-breaker posted today.
via Bing News